Innate Pharma (IPHA) Interest & Investment Income (2019 - 2025)

Innate Pharma has reported Interest & Investment Income for 7 years, with the latest figure at $7.8 million in Q2 2025.

• For the quarter ending Q2 2025, Interest & Investment Income rose 100.34% year-over-year to $7.8 million; the trailing twelve-month figure through Jun 2025 stood at $7.8 million (up 100.34% YoY), and the FY2025 full-year result was $9.3 million, up 42.48% from the prior year.
• Interest & Investment Income for Q2 2025 stood at $7.8 million, up from $3.9 million in the prior quarter.
• The five-year high for Interest & Investment Income was $7.8 million in Q2 2025, with the low at $3.4 million in Q2 2023.
• Historically, Interest & Investment Income has averaged $4.7 million across 5 years, with a median of $4.2 million in 2021.
• Annual changes were most pronounced in 2023 — Interest & Investment Income decreased 22.28% — and 2025, when it jumped 100.34%.
• Innate Pharma's Interest & Investment Income stood at $4.2 million in 2021, then advanced by 2.77% to $4.3 million in 2022, then declined by 22.28% to $3.4 million in 2023, then gained by 15.9% to $3.9 million in 2024, then jumped by 100.34% to $7.8 million in 2025.
• The last three Interest & Investment Income figures came in at $7.8 million (Q2 2025), $3.9 million (Q2 2024), and $3.4 million (Q2 2023), per Business Quant data.